Dr. Sridhar on Nab-Paclitaxel in Urothelial Cancer

Srikala Sridhar, MD, MSc
Published: Thursday, Jan 10, 2013

Srikala Sridhar, MD, MSc, medical oncologist, Princess Margaret Hospital, head of GU Medical Oncology Site Group, and assistant professor of Medicine, University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel (Abraxane) as a secondary treatment for urothelial cancer.

The trial enrolled 48 patients with metastatic urothelial cancer who had progressed on a cisplatin-based chemotherapy. All patients on the trial received nab-paclitaxel every 3 weeks at 260 mg/m2 with scans repeated every 6 weeks to assess response.

In the evaluable patients, the partial response rates were 32%. Overall, the median progression-free survival was 6 months and median overall survival was 10.8 months. These results are very impressive for a single-agent with tolerable toxicity in the second-line setting, expresses Sridhar.

Srikala Sridhar, MD, MSc, medical oncologist, Princess Margaret Hospital, head of GU Medical Oncology Site Group, and assistant professor of Medicine, University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel (Abraxane) as a secondary treatment for urothelial cancer.

The trial enrolled 48 patients with metastatic urothelial cancer who had progressed on a cisplatin-based chemotherapy. All patients on the trial received nab-paclitaxel every 3 weeks at 260 mg/m2 with scans repeated every 6 weeks to assess response.

In the evaluable patients, the partial response rates were 32%. Overall, the median progression-free survival was 6 months and median overall survival was 10.8 months. These results are very impressive for a single-agent with tolerable toxicity in the second-line setting, expresses Sridhar.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Genitourinary Malignancies™Sep 29, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x